You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Carbimazole ARISTO 5mg available from 20 November 2013
- Shortage of Neo-Mercazole (carbimazole)
For information on what you need to do between now and 20 November please read the Shortage of Neo-Mercazole (carbimazole) statement.
Update on supply of alternative product for Neo-Mercazole (carbimazole)
Link Healthcare has informed the TGA that it will be supplying Carbimazole ARISTO 5mg to pharmacies from 20 November 2013. This product has been authorised for supply by the Therapeutic Goods Administration as a replacement for Neo-Mercazole.
This product is available through normal prescribing practice and does not require the use of the Special Access Scheme. Therefore there will be no need to submit SAS Category B applications for its supply.
Patients can take their prescription to their pharmacy as normal from 20 November 2013.
There is a global shortage of Neo-Mercazole (carbimazole), which is often prescribed to people with an overactive thyroid (hyperthyroidism).